Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932263 | 0.83 | LMNA (0.48) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL1954 | 0.78 | ESR1 (0.53) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL5062426 | 0.77 | ALDH1A1 (0.56) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL2575993 | 0.77 | CYP2D6 (0.50) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL5933696 | 0.77 | LMNA (0.46) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL28198984 | 0.75 | SRC (0.46) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL1998001 | 0.75 | HCAR2 (0.58) | LMNAMAPK1CYP2D6SRCKMT2A | |
| SCHEMBL28057808 | 0.75 | LMNA (0.45) | LMNAMAPK1CYP2D6SRCCES2 | |
| SCHEMBL19260228 | 0.75 | TSHR (0.59) | LMNAMAPK1CES2CES1KMT2A | |
| SCHEMBL30722859 | 0.73 | HPGD (0.48) | LMNAMAPK1CYP2D6SRCCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137139-B1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEM (FR) | 2014-09-10 | — | — | EP | disclosed |
| US-8609882-B2 | Process for deacetalisation of α aminoacetals | CLARIANT SPECIALITY FINE CHEMICALS (FRANCE) (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2137139-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | Clariant Specialty Fine Chemicals (France) (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008125486-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | ALDH7A1, AADAT, AASDHPPT | LMNA 1751/4885MAPK1 3595/4885CYP2D6 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.